Sanofi SA (EPA:SAN) received a €82.00 ($96.47) price objective from investment analysts at UBS AG in a research note issued to investors on Monday, www.boersen-zeitung.de reports. The brokerage currently has a “neutral” rating on the stock.

SAN has been the subject of several other reports. Morgan Stanley set a €92.00 ($108.24) target price on shares of Sanofi SA and gave the company a “buy” rating in a research note on Friday, October 6th. S&P Global set a €90.00 ($105.88) target price on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Monday, July 31st. Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) target price on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Tuesday, October 17th. J P Morgan Chase & Co set a €90.00 ($105.88) target price on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Finally, BNP Paribas set a €85.00 ($100.00) target price on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of €88.12 ($103.67).

Shares of Sanofi SA (SAN) traded up 0.67% on Monday, reaching €84.37. 765,694 shares of the company traded hands. The firm has a market capitalization of €105.95 billion and a P/E ratio of 11.77. The stock has a 50-day moving average price of €26.13 and a 200 day moving average price of €26.02. Sanofi SA has a 1-year low of €24.55 and a 1-year high of €84.82.

TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/23/ubs-ag-reiterates-82-00-price-target-for-sanofi-sa-san.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.